Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of Subcutaneous Trastuzumab Deruxtecan in Metastatic Solid Tumors
jRCT2031250307Phase 1Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of trastuzumab deruxtecan in breast cancer, non-small cell lung cancer (NSCLC), Not applicable and 1 more (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of Participants Experiencing a Treatment Emergent Adverse Event (TEAE), Area Under Curve (AUC) and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)Not applicableMetastatic solid neoplasm
Beyond the preview
Go deeper on jRCT2031250307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250307.